AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AbSci (NASDAQ:ABSI) Rockets 12.78% as AI-Designed Antibody Shows Preclinical Hair Growth Potential
Generated by AI AgentBefore the BellReviewed byDavid Feng
Thursday, Dec 11, 2025 9:06 am ET1min read
Aime SummaryAbsci (NASDAQ:ABSI) surged 12.78% in pre-market trading on December 11, 2025, driven by promising preclinical data for its AI-designed antibody ABS-201.
The compound demonstrated potential to stimulate hair growth by inhibiting prolactin receptor (PRLR) signaling, extending the anagen (growth) phase of hair follicles, and preserving stem cell populations in human ex vivo studies. These findings, presented at a Key Opinion Leader seminar, highlight ABS-201’s ability to address unmet needs in androgenetic alopecia treatment, where current options like minoxidil and finasteride offer limited efficacy and notable side effects.
ABS-201’s mechanism targets follicular miniaturization, a key driver of pattern hair loss, by promoting vellus-to-terminal hair regeneration. The data suggest it could offer a disease-modifying approach distinct from existing therapies, with an interim Phase 1/2a trial readout anticipated in late 2026.
The stock’s recent momentum reflects growing confidence in the program’s potential to redefine hair loss treatment.
Before the Bell
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
United States Antimony Plunges 8.07% as Macroeconomic Shifts Spur Sector Rebalancing
Dec.11 2025
Mama's Creations Shares Plunge 8.59% as Regulatory Scrutiny and Retail Sector Weakness Weigh
Dec.11 2025
CapsoVision Inc. (NASDAQ:CV) Surges 32.73% as Senior VP of Finance Garcia's Track Record Fuels Growth Momentum
Dec.11 2025
AbSci (NASDAQ:ABSI) Rockets 12.78% as AI-Designed Antibody Shows Preclinical Hair Growth Potential
Dec.11 2025
JPMorgan Chase JPM Surges 3.1946% on Strategic Positioning, Regulatory Clarity, Cost Optimization
Dec.11 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet